Lotte Kleinendorst1,2,3, Ozair Abawi3,4, Hetty J van der Kamp5, Mariëlle Alders2, Hanne E J Meijers-Heijboer1,2, Elisabeth F C van Rossum3,6, Erica L T van den Akker3,4, Mieke M van Haelst1,2. 1. Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 3. Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 4. Department of Pediatrics, Division of Endocrinology, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands. 5. Department of Pediatrics, Division of Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. 6. Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
OBJECTIVE: Leptin receptor (LepR) deficiency is an autosomal-recessive endocrine disorder causing early-onset severe obesity, hyperphagia and pituitary hormone deficiencies. As effective pharmacological treatment has recently been developed, diagnosing LepR deficiency is urgent. However, recognition is challenging and prevalence is unknown. We aim to elucidate the clinical spectrum and to estimate the prevalence of LepR deficiency in Europe. DESIGN: Comprehensive epidemiologic analysis and systematic literature review. METHODS: We curated a list of LEPR variants described in patients and elaborately evaluated their phenotypes. Subsequently, we extracted allele frequencies from the Genome Aggregation Database (gnomAD), consisting of sequencing data of 77 165 European individuals. We then calculated the number of individuals with biallelic disease-causing LEPR variants. RESULTS: Worldwide, 86 patients with LepR deficiency are published. We add two new patients, bringing the total of published patients to 88, of which 21 are European. All patients had early-onset obesity; 96% had hyperphagia; 34% had one or more pituitary hormone deficiencies. Our calculation results in 998 predicted patients in Europe, corresponding to a prevalence of 1.34 per 1 million people (95% CI: 0.95-1.72). CONCLUSIONS: This study shows that LepR deficiency is more prevalent in Europe (n = 998 predicted patients) than currently known (n = 21 patients), suggesting that LepR deficiency is underdiagnosed. An important cause for this could be lack of access to genetic testing. Another possible explanation is insufficient recognition, as only one-third of patients has pituitary hormone deficiencies. With novel highly effective treatment emerging, diagnosing LepR deficiency is more important than ever.
OBJECTIVE: Leptin receptor (LepR) deficiency is an autosomal-recessive endocrine disorder causing early-onset severe obesity, hyperphagia and pituitary hormone deficiencies. As effective pharmacological treatment has recently been developed, diagnosing LepR deficiency is urgent. However, recognition is challenging and prevalence is unknown. We aim to elucidate the clinical spectrum and to estimate the prevalence of LepR deficiency in Europe. DESIGN: Comprehensive epidemiologic analysis and systematic literature review. METHODS: We curated a list of LEPR variants described in patients and elaborately evaluated their phenotypes. Subsequently, we extracted allele frequencies from the Genome Aggregation Database (gnomAD), consisting of sequencing data of 77 165 European individuals. We then calculated the number of individuals with biallelic disease-causing LEPR variants. RESULTS: Worldwide, 86 patients with LepR deficiency are published. We add two new patients, bringing the total of published patients to 88, of which 21 are European. All patients had early-onset obesity; 96% had hyperphagia; 34% had one or more pituitary hormone deficiencies. Our calculation results in 998 predicted patients in Europe, corresponding to a prevalence of 1.34 per 1 million people (95% CI: 0.95-1.72). CONCLUSIONS: This study shows that LepR deficiency is more prevalent in Europe (n = 998 predicted patients) than currently known (n = 21 patients), suggesting that LepR deficiency is underdiagnosed. An important cause for this could be lack of access to genetic testing. Another possible explanation is insufficient recognition, as only one-third of patients has pituitary hormone deficiencies. With novel highly effective treatment emerging, diagnosing LepR deficiency is more important than ever.
Authors: Omar Delannoy-Bruno; Chandani Desai; Juan J Castillo; Garret Couture; Ruteja A Barve; Vincent Lombard; Bernard Henrissat; Jiye Cheng; Nathan Han; David K Hayashi; Alexandra Meynier; Sophie Vinoy; Carlito B Lebrilla; Stacey Marion; Andrew C Heath; Michael J Barratt; Jeffrey I Gordon Journal: Proc Natl Acad Sci U S A Date: 2022-05-09 Impact factor: 12.779
Authors: Niels Vos; Sabrina M Oussaada; Mellody I Cooiman; Lotte Kleinendorst; Kasper W Ter Horst; Eric J Hazebroek; Johannes A Romijn; Mireille J Serlie; Marcel M A M Mannens; Mieke M van Haelst Journal: Curr Diab Rep Date: 2020-07-30 Impact factor: 4.810
Authors: Lotte Kleinendorst; Ozair Abawi; Bibian van der Voorn; Mieke H T M Jongejan; Annelies E Brandsma; Jenny A Visser; Elisabeth F C van Rossum; Bert van der Zwaag; Mariëlle Alders; Elles M J Boon; Mieke M van Haelst; Erica L T van den Akker Journal: PLoS One Date: 2020-05-08 Impact factor: 3.240
Authors: Cornelis Jan De Groot; Christine Poitou Bernert; Muriel Coupaye; Karine Clement; Stavroula A Paschou; Evangelia Charmandari; Christina Kanaka-Gantenbein; Martin Wabitsch; Emilie P Buddingh; Barbara Nieuwenhuijsen; Ljiljana Marina; Gudmundur Johannsson; E L T Van Den Akker Journal: Endocrine Date: 2021-01-29 Impact factor: 3.633
Authors: Martin Wabitsch; Sadaf Farooqi; Christa E Flück; Natasa Bratina; Usha G Mallya; Murray Stewart; Jill Garrison; Erica van den Akker; Peter Kühnen Journal: J Endocr Soc Date: 2022-04-15